HBM Partners raises €90 million second fund
This article was originally published in Scrip
The investment management group, HBM Partners, has secured a first closing of €90 million for its HBM BioCapital II fund, which will now invest in privately owned European and North American companies in the pharma, medical device and diagnostics sectors, it said. The fund's focus will be on revenue-generating and late-stage product development companies, supporting them in growing and internationalising their businesses. Investments are expected to range between €5 million and €15 million.
You may also be interested in...
Danish firm Topotarget said it was 'very confident' that it will be able to raise its first milestone from partner, Spectrum Pharmaceuticals, by the third quarter as it reported that final top-line data confirm that the primary endpoint was met in the Phase II BELIEF trial investigating an intravenous formulation of the histone deacetylase (HDAC) inhibitor, belinostat, for peripheral T-cell lymphoma (PTCL).
AstraZeneca's Caprelsa (vandetanib) has become the first treatment to be approved for advanced medullary thyroid cancer (MTC) in Europe after being granted marketing authorisation by the European Commission.
Despite reporting positive weight loss data from the third of four Phase IIIa trials from the SCALE program investigating liraglutide (Victoza) for obesity Novo Nordisk has failed to dazzle analysts who have questioned the commercial potential of the drug in this arena.